SHUTTLE PHARMACTCLS HLDGS INC Stock Price, News & Analysis

Shuttle Pharmaceuticals (NASDAQ:SHPH) signed a definitive letter of intent on October 22, 2025 to acquire substantially all assets and liabilities of Molecule.ai for $10 million, payable in cash and Shuttle common stock with milestone‑contingent timing and mix. Molecule.ai provides an Agentic AI Mode that automates drug discovery workflows, including drug‑target interaction simulation and molecular property reasoning, which Shuttle says can shorten early R&D timelines by months. Shuttle plans to integrate the platform with its oncology programs to accelerate discovery of radiation sensitizers and create a self‑learning discovery engine with potential cross‑therapeutic licensing options.

Shuttle Pharmaceuticals (NASDAQ:SHPH) announced a definitive Letter of Intent dated October 21, 2025 to acquire substantially all assets of 1542770 BC Ltd. (Molecule) for approximately US $10 million in cash and stock, aiming to integrate Molecule.ai's predictive platform with Shuttle's lead radiotherapy sensitizer Ropidoxuridine (IPdR). The release reports Phase 2 glioblastoma progress (nearly half randomized; 84% completed all treatment cycles) and Orphan Drug designation for IPdR. The content discloses the author was paid USD $10,000 for sponsored coverage and contains forward-looking statements subject to closing and regulatory risks.

Shuttle Pharmaceuticals (NASDAQ: SHPH) announced a binding term sheet to acquire substantially all assets and liabilities of 1542770 BC Ltd. ("Molecule"), a Canadian AI molecular discovery company, for a $10 million total purchase price payable in cash and Shuttle common stock.

The final cash/equity mix will be determined by Shuttle and payments are subject to performance milestones. Closing requires mutual due diligence and execution of definitive agreements with customary conditions.

The company said the acquisition aims to expand Shuttle's AI molecular modeling and predictive analytics capabilities to support its precision radiotherapy drug-discovery pipeline.

Shuttle Pharmaceuticals (Nasdaq: SHPH) executed a non-binding letter of intent to acquire Molecule.ai, an AI drug-discovery platform founded by Dr. ZT Zhang, on October 10, 2025. The LOI contemplates Shuttle acquiring all rights to Molecule.ai and assuming its liabilities, with Molecule.ai extending its platform to support Drug-Target Interaction modeling and delivering a first version of an Agentic AI mode.

Consideration is a $10 million purchase price payable at closing in a mix of cash and Shuttle common shares and subject to milestone completion; specific milestone terms are to be determined by both parties.

Shuttle Pharmaceuticals (Nasdaq: SHPH) announced a non-binding letter of intent dated Oct 9, 2025 to acquire AI developer Molecule.ai for a $10 million purchase price payable at closing subject to milestones.

Molecule.ai provides an AI drug-discovery platform using LLMs with modules for molecule property prediction, drug-target interaction modeling, and an initial Agentic AI mode to automate multi-step discovery workflows. Shuttle will acquire all rights and assume liabilities; Molecule.ai will extend the platform and assist hiring. Consideration will be a mix of cash and Shuttle common shares tied to milestone completion.

Shuttle Pharmaceuticals (Nasdaq: SHPH), a specialty pharmaceutical company focused on improving radiation therapy outcomes, provided a Q2 2025 corporate update highlighting significant progress in its clinical trials. The company's Phase 2 trial of Ropidoxuridine for glioblastoma treatment has reached 63% enrollment, with 72% of enrolled patients completing all seven cycles and reporting good tolerability.

Key financial developments include securing $4.25 million through a private placement, ending Q2 with $4.8 million in cash. The company completed a reverse stock split for Nasdaq compliance and strengthened its leadership by appointing George Scorsis as Board Chairman and Christopher Cooper to the Board. The Phase 2 trial completion is expected in late 2025, with data readouts anticipated in 2026.

Shuttle Pharmaceuticals (Nasdaq: SHPH), a specialty pharmaceutical company focused on improving cancer radiation therapy outcomes, has completed a $4.25 million private placement with an accredited investor. The company issued 1,180,877 shares of common stock (or pre-funded warrants) at $3.60 per share, priced at-the-market under Nasdaq rules.

The net proceeds will be used for potential acquisitions, marketing, and general corporate purposes. WestPark Capital served as the exclusive placement agent. The company has agreed to file registration statements with the SEC for the resale of the shares and warrant shares.

Shuttle Pharmaceuticals (SHPH) has secured a $4.25 million private placement through a securities purchase agreement with an accredited investor. The company will issue 1,180,877 shares of common stock or pre-funded warrants at $3.60 per share, priced at-the-market under Nasdaq rules. The proceeds will support potential acquisitions, marketing, and general corporate purposes. WestPark Capital serves as the exclusive placement agent, with the offering expected to close around June 23, 2025. The securities are offered only to accredited investors and are not registered under the Securities Act of 1933. Shuttle Pharma has agreed to file registration statements for the resale of the shares and warrant-eligible shares.

Shuttle Pharmaceuticals (NASDAQ: SHPH) has announced a 1-for-25 reverse stock split effective June 16, 2025, at 12:01 a.m. ET. The company's common stock will continue trading under the symbol SHPH on the Nasdaq Capital Market with a new CUSIP number 825693401. The split will reduce outstanding shares from 26,210,037 to approximately 1,048,401 and will apply to RSU grants and warrants. Fractional shares will be rounded up to the next whole number. This strategic move aims to maintain Nasdaq listing compliance and strengthen the company's capital structure. Shuttle Pharma, a specialty pharmaceutical company, focuses on developing radiation sensitizers to improve outcomes for cancer patients undergoing radiation therapy.